ArticleInfection and immunity1998
Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).
Article in Infection and immunity, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- The grand escape - how pathogens outsmart the human complement system.Immunobiology · 2025Review
- Re-visiting humoral constitutive antibacterial heterogeneity in bloodstream infections.The Lancet. Infectious diseases · 2024Review
- Host heterogeneity in humoral bactericidal activity can be complement independent.Frontiers in immunology · 2024Article
- The immunopathogenesis ofFrontiers in microbiology · 2024Review
- Microbial evasion of the complement system: a continuous and evolving story.Frontiers in immunology · 2023Review
- Surface Modification ofMembranes · 2021Article
- The Functional Amyloid Curli Protects Escherichia coli against Complement-Mediated Bactericidal Activity.Biomolecules · 2018Article
- Biomedical applications of glycosylphosphatidylinositol-anchored proteins.Journal of lipid research · 2016Review
- Oral Campylobacter species: Initiators of a subgroup of inflammatory bowel disease?World journal of gastroenterology · 2015Review
- Protease-dependent mechanisms of complement evasion by bacterial pathogens.Biological chemistry · 2012Review
- Complement evasion by human pathogens.Nature reviews. Microbiology · 2008Review
- Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade.Infection and immunity · 2006Article
- The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.Infection and immunity · 2003Article
- BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition.Infection and immunity · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Protectin (CD59) is a glycophosphoinsitol (GPI)-anchored defender of human cells against lysis by the membrane attack complex of complement. In this study, we examined whether protectin released from human cell membranes can incorporate into the surface of gram-negative bacteria. Analysis by using radiolabeled protectin, immunofluorescence, flow cytometry, and whole-cell enzyme-linked immunosorbent assay demonstrated that protectin bound to nonencapsulated Escherichia coli EH237 (Re) and EH234 (Ra) in a calcium-dependent manner. The incorporation required the GPI-phospholipid moiety since no binding of a phospholipid-free soluble form of protectin was observed. Mg2+ did not enhance the binding, and a polysialic acid capsule prevented it (strain IH3080 [O18:K1:H8]). Bound protectin inhibited the C5b-9 neoantigen expression on complement-treated bacteria. Protection against complement lysis was observed in both a colony counting assay and a bioluminescence assay, where viable EH234 bacteria expressing the luciferase gene emitted green light in the presence of the luciferine substrate. In general, two- to four-times-higher serum concentrations were needed to obtain 50% lysis of protectin-coated versus noncoated bacteria. The results indicate that protectin can incorporate in a functionally active form into the cell membranes of the two nonencapsulated deep rough E. coli strains studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.